Rockwell Medical, Inc. · NASDAQ:RMTI
Rockwell Medical — Investor Presentation (March 2025)
18 slides from Rockwell Medical's investor presentation, Mar 20, 2025
Slide 1: Investor Presentation
Investor Presentation March 20, 2025 RMTI
Slide 2: Forward-Looking Statements and Non-GAAP Measures
Forward-Looking Statements and Non-GAAP Measures Certain statements in this presentation may constitute “forward-looking statements” within the meaning of federal securities laws, including, but not limited to, Rockwell's expectations regarding revenue, profitability, financial position, 2024, 2025
Slide 3: Rockwell Medical At A Glance
Rockwell Medical At A Glance Healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. Business ‘ Largest supplier of liquid bicarbonate hemodialysis concentrates in the U.S. Overview Second largest supplier
Slide 4: Executive Management Team
Executive Management Team Chief Corporate Chief Executive Officer Chief Financial Officer Chief Legal Officer Chief Commercial Officer Affairs Officer Dr. Mark Strobeck Jesse Neri Megan Timmins Tim Chole Heather Hunter Aquio Assernos ARUVANT VANT aramark 3 Baxter E& (@PCAREY) fesk] () sR One —-, ASS
Slide 5: Corporate Strategy
Corporate Strategy vw 8 & Provide Customers with the Diversify our Customer Optimize our Business through Achieve Sustainable Highest Quality and Most Base and Product Portfolio Continued Manufacturing Profitability Reliable Products and Services Improvements RMTI © 2025 Rockwell Medical, Inc. (© RO
Slide 6: Leading Manufacturer and Supplier of Concentrates
Leading Manufacturer and Supplier of Concentrates Hemodialysis is a Necessity for End Stage Renal Disease Patients * Approximately 475,000 patients in the U.S. require in-center hemodialysis annually’). * Each patient receives approximately 3 treatments per week, totaling ~150 in-clinic procedures p
Slide 7: U.S. In-Center and Acute Care Hemodialysis Concentrates TAM
U.S. In-Center and Acute Care Hemodialysis Concentrates TAM ~4-6% CAGR driven primarily by increasing number of patients suffering from end-stage kidney disease 2024 2028 ‘SOURCE: CAGR based on “Rockwell Medical: Concentrates Growth Strategy Report”, LE.K. Consulting LLC (2022) RMTI © 2025 Rockwell
Slide 8: Key Drivers to Diversify our Customer Base and Product Portfolio
Key Drivers to Diversify our Customer Base and Product Portfolio Increase market share throughout the U.S. Several small, regional hemodialysis and internationally. Rockwell continues to concentrates manufacturers. Opportunity secure commercial partnerships and seeks for consolidation and modernizat
Slide 9: Expanded Product Portfolio
Expanded Product Portfolio with Bicarbonate Cartridge Premium grade, single-use bicarbonate cartridges offered in two sizes: 720g and 900g. 510(k) approved. Single-use bicarbonate disposables represent an approximate $100 million market opportunity. One of the fastest growing segments within the hem
Slide 10: Financials and Milestones
(©ROCKWELL MEDICAL Financials and Milestones
Slide 11: Continue to Improve Rockwell's Financial Health
Continue to Improve Rockwell’s Financial Health Generated Highest Annual Revenue and Gross Profit to Date Three Months Ended Twelve Months Ended December 31 December 31 (in Millions, Except Per Share Amounts) Net Sales $ 24.7 Gross Profit $ 3.6 Operating Income (Loss) $ (0.5) Net Income (Loss) $ (0.
Slide 12: Achieved Record Net Sales, Gross Profit and Gross Margin in 2024
Achieved Record Net Sales, Gross Profit and Gross Margin in 2024 Gross Profit (Loss) ($ in millions) (S$ in millions) $100 $95 $90 $85 $80 $75 $70 $65 $60 2021 2022 2023 2024 2021 2022 2023 RMTI © 2025 Rockwell Medical, Inc. Nasdag Listes 2024 Gross Margin © ROCKWELL MEDICAL
Slide 13: Achieved Profitability on an Adjusted EBITDA Basis for FY'24
Achieved Profitability on an Adjusted EBITDA Basis for FY’24 ($ in millions) $(28.4) | 2 | RMT! © 2825 necro Medical nc. ROCKWELL
Slide 14: 2025 Guidance
2025 Guidance Net Sales* $65.0M - $70.0M Zz Ce Adjusted EBITDA ($0.5)M - $0.5M © 2025 Rockwell Medical, Inc. al Gross Margin 16% to 18% lon and/or © ROCKWELL MEDICAL
Slide 15: 2025 Projected Milestones
2025 Projected Milestones Achieve sustained profitability for FY’25 on an adjusted EBITDA basis. Grow concentrates business by adding new customers. Expand contracts and partnerships with existing customers Continue to optimize our business through improved processes and expanded automated manufactu
Slide 16: Why Invest in Rockwell Medical?
Why Invest in Rockwell Medical? Y¥ Experienced Management Team Y Large and Growing Market Opportunity v¥ Revenue-Generating Business Y Profitable, Strong Financials Y Attractive Valuation | RMTI ena wueuue © ROCKWELL MEDICAL
Slide 17: () ROCKWELL
() ROCKWELL MEDICAL QRockweu www.rockwellmed.com IR@rockwellmed.com
Slide 18: Reconciliation to GAAP Financial Measures
Reconciliation to GAAP Financial Measures Non-GAAP Financial Measures To supplement the Company's financial results presented on a U.S. generally accepted accounting principles ("GAAP") basis, the Company has included information about non-GAAP measures of EBITDA and adjusted EBITDA as useful operat
Rockwell Medical — Investor Presentation (March 2025) on 6ix